Drug Profile
HIV combination vaccine - GSK
Alternative Names: HIV gp120/NefTat/AS02A vaccine - GSK; NefTat + gp120W61DLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK; International AIDS Vaccine Initiative; National Institute of Allergy and Infectious Diseases
- Class AIDS vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported HIV-1 infections
Most Recent Events
- 28 May 2018 No recent reports of development identified for phase-I development in HIV-1-infections(Prevention) in USA (IM, Injection)
- 28 May 2018 No recent reports of development identified for phase-I development in HIV-1-infections(Prevention, In volunteers) in Africa (IM, Injection)
- 17 May 2016 This programme is still active